Space Peptides appoints Dr. Simon Nebel as Business advisor

Space Peptides Pharmaceutical is pleased to welcome Dr. Simon Nebel as Business Advisor. Dr. Simon Nebel has participated in the financing of a number of life science companies and the M&A transactions for Aravis portfolio companies. Simon has been the board member or observer in fourteen companies. Before joining Aravis, he was a group strategist […]

Space Peptides appoints Prof. Hans-Joachim Böhm as Scientific advisor

Space Peptides Pharmaceutical is pleased to welcome Prof. Hans-Joachim Böhm as Scientific advisor. Prof. Hans-Joachim Böhm is a professor of Bioinformatics at the University of Basel, working on the development of new methods for computer-aided drug design, as well as a member of the Swiss Science Council. He worked for several years at Roche in […]

Space Peptides extends its strategic collaboration with the University of Bern, Switzerland, to the next 5 years

Space Peptides announces that it decided to extend its collaboration with the University of Bern, Switzerland, for the next 5 years, aiming to continue to build on the success of the precedent years of successfully accelerating translational research projects as well as building a strong cohort of scientists with in-depth knowledge of AI-based drug discovery from both the academic and […]

Opening ceremony celebrates the construction for Space Peptides of a large-scale peptide manufacturing facility in Jiangsu, China

Space Peptides will invest approximately USD 150 million to build state-of-the-art manufacturing facilities, expanding to an annual capacity of 1100 kg to support scaling of peptide active pharmaceutical ingredient production to clinical and commercial manufacturing, covering therapeutic areas of women’s health, metabolic diseases, antimicrobial and onco-immunology. The new facility will have an area of approximately […]

Space Peptides completes GMP-like inspection by China’s National Medical Products Administration (NMPA, previously called CFDA)

Space Peptides successfully completes the GMP inspection carried out by China’s regulatory agency National Medical Products Administration (NMPA, previously called CFDA). The comprehensive inspection covered the Space Peptides Xiamen facility’s quality processes and entire production system., which meets the requirements for producing peptide intermediates / advanced intermediates and active pharmaceutical ingredients (APIs) for clinical trial […]

Space Peptides announces its new <em>in vitro / in vivo</em> testing laboratory at the Xiamen Science Park in China

“With our new in vitro / in vivo testing laboratory closely connected with the peptide production site, Space Peptides provides integrated peptide drug discovery from computational prediction, peptide synthesis and laboratory testing results, forming close iterative cycles”, said Dr. Runze He, CEO at Space Peptides. “Operational this month, the testing facility at Xiamen National Science […]

GDBspace publishes in Drug Target Review

GDBspace AG, a company specializing in computational methods for molecule discovery, discusses a novel cheminformatics approach for drug discovery, in Drug Target Review, Volume 7, Issue 02, Summer 2020.